



Alpha

Launch of new Pre-Formulation and Drug Product Development Laboratory at Alphora


Eurofins Alphora is pleased to announce the expansion of services into pre-formulation and oral product formulation development. Our new service offerings coupled with existing physicochemical characterization now position Alphora as a full service CDMO with specific IND enabling capabilities. With investment and an expanded Ph.D. team, Alphora has enhanced its ability to engineer and optimize drug candidates.



Kevin Rosenthal
*Business Head, Formulations &
Finished Product Operations*

As a follow on to Pre-formulation and formulation development, Alphora is in the process of bringing on line a new clinical manufacturing suite. Scheduled to come on line in March 2019, the new production suite will provide clinical manufacturing of oral dosage forms with a focus on first-in-human and quick to clinic strategies.

Mirco-dissolution and micro-flux technologies are core technologies in the new Pre-formulation lab which allow the rank ordering of polymorphs and salts to drive API Quality by Design and yield the most "drugable" candidate for further CMC development and IND studies. Solubility enhancement is driven through new capabilities in jet milling and spray drying (micronization and amorphous dispersions). Excipient screening and prototype formulation development are supported through photo stability and validated ICH stability systems and a compliment of analytical equipment such as USP dissolution, HPLC and Karl Fischer.



For additional information on this news release or about Eurofins Alphora, please contact:

Rav Mahal, Ph.D. Vice President, Business Development and Project Management
E-mail: rav.mahal@alphoraresearch.com, or: info@alphoraresearch.com

2395 Speakman Drive, Suite 2001, Mississauga, Ontario, Canada L5K 1B3 Tel: 905 403-0477 alphoraresearch.com

